Advancing RNA is a Life Science Connect community focused on the rapidly evolving field of RNA-based therapeutics. It aims to provide valuable insights, discussions, and resources for professionals developing RNA-based drugs. Primary members of the community consist of individuals from biopharma organizations engaged in pre-BLA development, often in the pre-IND discovery stage. The community addresses various challenges in RNA therapy development, including analytical, quality, manufacturing, and regulatory issues. Additionally, Advancing RNA is positioned within the broader Life Science Connect network, allowing members to access additional resources as needed for their RNA therapy development journey.

The Society for RNA Therapeutics (SRT) is a global network to support translational research and development of RNA therapeutics; to develop standards for RNA manufacturing, guidelines for clinical trials, and to facilitate public-private-regulatory partnerships and to advocate for accessible RNA therapeutics for all patients.

SRT aims to provide public and professional education and develop training guidelines; to advocate for patients with diseases amenable to RNA therapies; to develop clinical best practices in RNA therapeutics; to support early career and professional development; and to advocate accessibility to RNA therapeutics for low and middle income countries for the enhancement of global health.

The Alliance for mRNA Medicines (AMM) is dedicated to advancing and advocating for an RNA platform approach to medicine, including protein replacements, gene editing and cell engineering strategies, immunotherapies and vaccines to treat cancer, rare disease, autoimmunity and other chronic and infectious illnesses for the benefit of patients, public health, and society.

We advance this mission by shaping policy, accelerating regulatory science, expanding access, and enabling manufacturing — while convening the scientists, innovators, and industry leaders who are turning RNA’s promise into reality. Our goal is simple: ensure that transformative RNA medicines reach every patient who needs them.